News | April 07, 2025
Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The company expects to launch this product through its marketing partner in the near future
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA
According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of approximately $39.3 mn
PRX-PLUS has a unique product feature with its deep-impacting formula
The introduction of Coveris’ sleeve-to-sleeve PCR model complements sectors such as bottling where an established recycling infrastructure exists
GE HealthCare’s Revolution Vibe CT enables more facilities to elevate patient care by offering advanced cardiac imaging technology
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Subscribe To Our Newsletter & Stay Updated
